Abstract
Azithromycin is a cyclic-structure macrolide, shows prolonged anti-bacterial, anti-inflammatory and immunomodulatory effects. Azithromycin belongs to BCS class II drug i.e. drug with poor solubility and good permeability. The major problems with this drug is its very poor solubility in biological fluids that results into poor bioavailability after oral administration. The objectives of the present research work were to develop the formulation with enhanced dissolution rate of poorly soluble azithromycin. The solid dispersion of azithromycin was prepared using carrier PEG -6000 by melting method. Tablets were formulated containing solid dispersion products and compared with tablet formulated by pure drug without any carrier. The in vitro dissolution studied showed improved dissolution rate and it was compared with in vivo studied using animal model. Dissolution enhancement of the drug being caused by change in crystalline nature of drug in to amorphous nature.
References
Drew RH and Gallis HA. Azithromycin–spectrum of activity, pharmacokinetics,and clinical applications. Pharmacotherapy 1992,12:161–7.
Spagnolo P, Fabbri LM and Bush A. Long-term macrolide treatment for chronic respiratory disease. EurRespir J 2013,42:239-251.
Albert RK, Connett J, and Bailey WC. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011,365:689-698.[View in PubMed]
Wong C, Jayaram L, and Karalus N. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): arandomised, double-blind, placebo-controlled trial. Lancet.2012,380:660-667.
Liu P, Allaudeen H, Chandra R, Phillips K, Jungnik A, Breen JD and Sharma A. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen, Antimicrob. Agents Chemother2007, 51:103-109.
Harahap A,Prasaja B, LusthomW, Hardiyanti,GintingMB and Lipin.A bioequivalence study of two azithromycin tablet formulations in Indonesian healthy subjects, Journal of Bioequivalence & Bioavailability 2012,4:48-49.
Shah J, Vasanti S, Anroop B and Vyas H. Enhancement of dissolution rate of valdecoxib by solid dispersions technique with PVP K 30 & PEG 4000: preparation and in vitro evaluation. J. Incl. Phenom. Macrocycl. Chem. 2009, 63:69–75.
Biswal S, Sahoo J, Murthy PN, Giradkar RP and Avari JG. Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000. AAPS PharmSciTech. 2008, 9: 563–570.[View in PubMed]
Rahman Z, Zidan AS, and Khan MA. Formulation and evaluation of a protein-loaded solid dispersions by non-destructive methods. AAPS J 2010,12: 158–170.[View in PubMed].
Patil MP and Gaikwad JN. Preparation and characterization of gliclazide-polyethylene glycol 4000 solid dispersions. Acta Pharm.2009, 59:57–65.
Wlodarski K, Tajber L and Sawicki W. Physicochemical properties of direct compression tablets with spray dried and ball milled solid dispersions of tadalafil in PVP-VA. European Journal of Pharmaceutics and Biopharmaceutics2016, 109:14–23.
Arora SC,Sharma PK, Irchhaiya R, Khatkar A, Singh N and Gagoria J. Development, characterization and solubility study of solid dispersions of azithromycin dihydrate by solvent evaporation method. J Adv Pharm Technol Res 2010,1: 221–228.[View in PubMed]
Singh AK, Chakrabarti A and Garg SK. A study on bioavailability of theophylline in rabbits as influenced by fatty diet.Indian J Physiol pharmacol 1991, 35: 130-134.
Zeng F, Wang L, Zhang W, Shi K and Zong L. Formulation and in vivo evaluation of orally disintegrating tablets of clozapine/hydroxypropyl-β-cyclodextrin inclusion complexes, AAPS PharmSciTech 2013,14: 854–860.[View in PubMed]
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array